Isotretinoin trial

This information was retrieved directly from the website clinicaltrials. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials. Allow cookies Manage Settings. Please choose all settings. Allow cookies Save Settings.

Placebo for constipation. Radiostereometry in the Assessment of Knee Prosthesis Study. Study of efficacy of CNP in subjects with peanut allergy. One potential mechanism of such an effect, however, is that isotretinoin can increase levels of the serum marker of DNA oxidative damage 8-hydroxydeoxyguanosine 8-OHdG and decrease total antioxidant status, as was observed by Georgala et al. The authors suggested that serum levels of 8-OHdG in patients taking isotretinoin may increase from a direct effect of isotretinoin on liver, muscle, and epidermal cells.

This hypothesis is supported by data indicating that 8-OHdG and other products of oxidative DNA damage and repair are associated with a susceptibility to lung cancer Again, these mechanistic speculations are more academic than practical since we believe the finding of increased SPTs in never smokers taking isotretinoin very likely was an artifact of a very small subgroup analysis.

The present analyses indicate that isotretinoin administered over a protracted period of time potentially was harmful in current smokers, although the overall mortality HR lessened in this extended follow-up, and safe in the combined group of never smokers and former smokers. Despite clinical, biological, and dosing differences between our lung cancer population and other retinoid users such as young people taking isotretinoin for severe cystic or nodular acne, our present findings may have public health implications for the use of retinoids.

The authors thank Susan P. Ackermann Shiff and Xian Zhou for their earlier involvement in the study. Hoffmann-La Roche. The data collection, management, and analysis were performed by M. Anderson personnel independent from Hoffmann-La Roche. Daniel S. Reshef was also involved in the study design and data interpretation.

National Center for Biotechnology Information , U. Cancer Prev Res Phila. Author manuscript; available in PMC Jun 1. Reshef , 2 Anita L.

Wistuba , 3, 5 Reuben Lotan , 3 and Scott M. Lippman 3. Jack Lee. Reshef 2 Hoffmann-La Roche Inc. Anita L. Ignacio I. Scott M. Author information Copyright and License information Disclaimer. Requests for reprints: J. Jack Lee, Ph. Copyright notice. The publisher's final edited version of this article is available free at Cancer Prev Res Phila. See other articles in PMC that cite the published article. Associated Data Supplementary Materials 1. Methods The protocol amendment for the extended follow-up of the LIT was reviewed and approved by the M.

Results The study population had an average age of 64 years and median age of 65 years. Table 1 Causes of death in each treatment arm. Open in a separate window. Table 2 Cause-specific deaths for isotretinoin versus placebo by the Cox proportional hazards model and cumulative-incidence analysis by the K-sample test.

Table 3 Multi-covariate mortality analysis Cox model. Discussion The treatment-by-smoking interactions of the original LIT analysis--harm in current smokers and benefit in never smokers--weakened in the extended analysis, which added more events collected after treatment had stopped. Supplementary Material 1 Click here to view. Acknowledgment The authors thank Susan P. Footnotes The data collection, management, and analysis were performed by M.

References 1. Cancer statistics, On the other hand, they found 6 drugs in CMAP that are currently being investigated in clinical trials for treating COVID chloroquine, thalidomide, methylprednisolone, losartan, lopinavir and ritonavir, from clinicaltrials. The study is a randomized interventional comparative Phase III trial. The duration of the trial for each subject is expected to be 3 months. The duration for each individual subject includes one-month study treatment and 3 months follow-up time.

Recruitment of subjects will start in April Trial population will consist of both genders. Name of tested drug: Isotretinoin. All consenting adult patients having confirmed COVID will be recruited and randomly and blindly allocated in a ratio to the following arms:. Group 1 : 50 patients will receive isotretinoin 0. Talk with your doctor and family members or friends about deciding to join a study.

To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Try the modernized ClinicalTrials. Patients were further followed for eight weeks to see any relapse.

Side-effects were also recorded.